Results 151 to 160 of about 290,024 (350)

PARP Inhibition Activates STAT3 in Both Tumor and Immune Cells Underlying Therapy Resistance and Immunosuppression In Ovarian Cancer [PDF]

, 2021
Antons Martincuks, Jieun Song, Adrian Kohut, Chunyan Zhang, Yijia Li, Qianqian Zhao, Edward Mak, Lorna Rodrı́guez-Rodrı́guez, Hua Yu, Mihaela Cristea   +9 more
openalex   +1 more source

Combined Photothermal and mTOR‐Targeted Therapy Overcomes Immune Evasion and Enhances Checkpoint Blockade Efficacy in Metastatic Triple‐Negative Breast Cancer

Advanced Science, EarlyView.
This study reveals that photothermal therapy, while inducing immunogenic cell death in triple‐negative breast cancer, paradoxically activates the oncogenic mTOR pathway to drive immune evasion. To counter this, a smart nanocomposite is engineered to co‐deliver localized hyperthermia and mTOR inhibition.
Yujie Zhao, Jing Yu, Xin Wang, Xu Liu, Fengli Zuo, Tianyue Xu, Leyi Tang, Ling Xiong, Li Li, Huifang Li, Xiaoting Chen, Guang Yang, Jing Jing, Xiaowei Liu   +13 more
wiley   +1 more source

NIR‐Activatable Domino Cascade Catalysis Nanozyme Reactor for Multi‐Mechanism Synergistic Immunotherapy in Bladder Cancer

Advanced Science, EarlyView.
This study presents an intravesical delivery strategy of ferroptosis‐ and immunity‐inducing nanozyme‐loaded thermoresponsive hydrogels (FMCC@PNH) for enhanced bladder cancer therapy. Abstract Current intravesical therapies for bladder cancer after resection are limited by poor tissue penetration, off‐target effects, and insufficient efficacy.
Yongnan Jiang, Qingling Zhang, Yuhan Zhang, Xinlu Yu, Bo Jia, Yulong Dong, Yalong Wu, Kelong Fan, Xinquan Gu, Lei Ji, Wei Jiang, Bin Liu   +11 more
wiley   +1 more source

Immunosuppression in stem cell clinical trials of neural and retinal cell types: A systematic review.

PLoS ONE
BackgroundPharmacologic immunosuppression regimes are commonly employed in stem cell clinical trials to mitigate host immune rejection and promote survival and viability of transplanted cells.
Shravan Gowrishankar, Matthew E Smith, Nathan Creber, Jameel Muzaffar, Daniele Borsetto   +4 more
doaj   +1 more source

Mechanisms of sepsis‐induced immunosuppression and immunological modification therapies for sepsis [PDF]

, 2018
Satoshi Ono, Hironori Tsujimoto, Shuichi Hiraki, Suefumi Aosasa   +3 more
openalex   +1 more source

5′tRF‐GlyGCC Promotes Breast Cancer Progression via LDHA‐Mediated Glycolysis and Macrophage Polarization

Advanced Science, EarlyView.
5’tRF‐GlyGCC promotes breast cancer malignancy by binding to LDHA. This interaction, facilitated by FGFR1 and LDHA phosphorylation, enhances glycolysis. Additionally, 5’tRF‐GlyGCC/LDHA signaling recruits and polarizes macrophages into a pro‐tumor M2 state via CCL7, thus remodeling the tumor microenvironment.
Cheng Yi, Yunqing Lu, Xing Chang, Ying Wang, Jiawang Zhou, Guoyou Xie, Lijun Tao, Zhaotong Wang, Yifan Tian, Lihong Wang, Feng Tang, Yijing Zheng, Xinchen Yue, Jinping Lei, Xiansong Wang, Lichen Ge, Zhuojia Chen, Hongsheng Wang   +17 more
wiley   +1 more source

Liver transplantation [PDF]

, 2014
Purpose of review: Long-term survival of liver transplant recipients is threatened by increased rates of de-novo malignancy and recurrence of hepatocellular carcinoma (HCC), both events tightly related to immunosuppression.
Burroughs, AK, De la Mata, M, Rodríguez-Perálvarez, M   +2 more
core  

The KDM6B/SLC10A2 Axis Suppresses MDSCs Recruitment via ERK/AP‐1 Signaling in Colorectal Cancer

Advanced Science, EarlyView.
In wild‐type intestinal epithelial cells, KDM6B demethylates SLC10A2 to promote its expression, after which SLC10A2 suppresses ERK phosphorylation, inhibiting AP‐1 (Fos/Jun) transcription and chemokine production. In KDM6B‐deficient intestinal epithelial cells, SLC10A2 methylation increases, and its expression decreases.
Zhibo Hu, Jing Xun, Bin Liu, Xiaolin Jiang, Yingdi Han, Huichao Yang, Qi Gao, Ruifang Gao, Aimin Zhang, Xueliang Wu, Dapeng Zhang, Dihua Li, Tian Li, Shimin Yang, Ximo Wang, Xiangyang Yu, Qi Zhang   +16 more
wiley   +1 more source

Risks and benefits of weaning immunosuppression in liver transplant recipients: Long-term follow-up [PDF]

, 1997
Flynn, B, Fung, JJ, Marino, I, Mazariegos, GV, Reyes, J, Starzl, IE   +5 more
core   +1 more source

Post-transplant aspergillosis and the role of combined neurosurgical and antifungal therapies under belatacept immunosuppression.

, 2011
Ekkehard M. Kasper, Jiří Bártek, Scott Johnson, Burkhard S. Kasper, Martha Pavlakis, Michael Wong   +5 more
openalex   +2 more sources